4-{[2-(2-methoxybenzyl)-3-oxo-1,2,3,4,6,7-hexahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzonitrile | 1331733-08-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[2-(2-methoxybenzyl)-3-oxo-1,2,3,4,6,7-hexahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzonitrile
• 英文别名: 4-[[2-[(2-Methoxyphenyl)methyl]-3-oxo-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]methyl]benzonitrile
• CAS: 1331733-08-4
• 化学式: C₂₂H₂₂N₄O₂
• 分子量: 374.442
• InChiKey: BQGAGLRRHJUASH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PYRAZOLE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120316172A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula IA and IB wherein R 1 , R 2 , R 3 , R 4 and Z are as defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及式IA和IB的化合物，其中R1、R2、R3、R4和Z如本文所定义，或其药学上适宜的酸盐。式IA和IB的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• [EN] PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLO PIPÉRIDINE EN TANT QU'INHIBITEURS DE LA NADP OXYDASE
  申请人：GENKYOTEX SA

  公开号：WO2011101804A1

  公开（公告）日：2011-08-25

  The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的吡唑吡啶衍生物，其制药组合物以及它们用于治疗和/或预防与尼古酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。
• Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
  申请人：GenKyoTex SA

  公开号：EP2361911A1

  公开（公告）日：2011-08-31

  The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及Formula (I)的吡唑哌啶衍生物、其药物组合物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。
• Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors
  申请人：Page Patrick

  公开号：US20120316163A1

  公开（公告）日：2012-12-13

  The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑啉哌啶衍生物、其制药组合物以及它们在治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）有关的疾病或症状方面的应用。
• PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：GenKyoTex SA

  公开号：EP2536723B1

  公开（公告）日：2013-12-11